Transdermal Drug Delivery System Market Size & Forecast Report, 2013 - 2024

Global transdermal drug delivery system market is anticipated to reach USD 81.4 billion by 2024 owing to shift toward sedentary lifestyle that encourages chronic disorders. Transdermal drug delivery is a painless process of delivering drug in the body part. TDDS delivers drug through the skin in pre-decided and regulated rate. It offers extended therapeutic effects, lesser side-effects, improved patient compliance, better bioavailability, and easy cessation of drug treatment. Transdermal drug delivery is much preferred today as compared to the conventional oral method or injectables.

Transdermal drug delivery systems market is witnessing growth due to the factors like increasing consumer preference for minimally invasive procedures for chronic disorders and multiple advantages associated with TDDS. Infusion of drug could be effectively monitored and projected creditably through transdermal drug delivery method, which makes it convenient to maintain steady level of drug. However, transdermal drug delivery system industry is restrained by constrained areas of delivery and slow infusion rate hydrophilic drugs.

Recent years has introduced multiple drugs that could be delivered through transdermal route. Also, the existing market players in this market are focusing on mergers and acquisition to create niche market.Transdermal drug delivery system market is categorized on the basis of delivery system type, application, and geography. On the basis of delivery system type, the market is divided into active (matrix system, reservoir system), passive (electrical based, structure based) and others. Electrical based systems can be further classified as iontophoresis, electroporation and sonophoresis. Passive delivery system segment is predicted to lead the market of transdermal drug delivery system due to rise in chronic disorders.

Based on application, transdermal drug delivery systems industry is divided into analgesics, hormone replacement therapy, motion sickness, cardiovascular disorder, smoking cessation, and others. Cardiovascular disorder segment is projected to hold larger market share of transdermal drug delivery system owing to the increase in cases of heart-related disorders.

Geographically, transdermal drug delivery systems market is segmented as North America, Latin America, Europe, Asia Pacific and Middle East & Africa. Asia Pacific is expected to dominate transdermal drug delivery system industry owing to the growing number of patients suffering from chronic disorders. The prominent players in transdermal drug delivery systems industry include Acrux Limited, Echo Therapeutics, Inc., Johnson & Johnson, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Mylan N.V., Bayer AG, Endo Pharmaceuticals Inc. and Novartis AG.

Market Segment:

Global Transdermal Drug Delivery Systems Product Outlook (Revenue, USD Billion, 2013 - 2024)
    • Electroporation
    • Radiofrequency
    • Iontophoresis
    • Microporation
    • Thermal
    • Mechanical arrays
    • Ultrasound
    • Others

Global Transdermal Drug Delivery Systems Application Outlook (Revenue, USD Billion, 2013 - 2024)
    • Central nervous system
    • Pain management
    • Cardiovascular
    • Hormone
    • Others

Transdermal Drug Delivery Systems Regional Outlook (Revenue, USD Billion, 2013 - 2024)
    • North America
        • U.S.
        • Canada
    • Europe
        • UK
        • Germany
    • Asia Pacific
        • Japan
        • China
        • India
    • Latin America
        • Mexico
        • Brazil
    • MEA
        • South Africa